LUDC-IRC Precision Medicine Symposium
Type 2 diabetes and related conditions are rising rapidly around the global and conventional prevention and treatment strategies are failing to keep pace. Thus, new approaches, including those focused on patient-level biomarker data to optimize advice and therapies, have garnered tremendous interest; this is broadly termed “precision medicine”. The LUDC-IRC precision medicine symposium will bring together several outstanding international experts on precision medicine, along with junior and senior investigators from LUDC-IRC to describe and discuss cutting-edge research germane to this topic. Lectures will cover the tremendous opportunities offered through private-public partnerships; the major diabetes associations’ (ADA and EASD) perspectives; the interrogation of big data using state-of-the-art bioinformatics; translation of basic science to clinical practice; innovative trial designs; and the critical role of lifestyle in diabetes and malignancies.
Welcome and overview
09-00-09-15 Paul Franks, LUDC
Session 1: Precision medicine - Swedish, US and Europen perspectives
09:15-10:00 Maria Gomez, LUDC
"The power of private-public partnerships in precision medicine"
10:00-10:45 Will Cefalu, American Diabetes Association, US
"Revolutionizing diabetes management: emerging concepts for an individualized approach for Standards of Care”"
10:45-11:00 Coffe break
11:00-11:45 John Nolan, EASD
"Towards personalized and precision care of diabetes in Europe"
Session 2: Genetic and non-genetic biomarkers in large population cohorts
13:00-13:30 Louise Brunkwall, LUDC
"The human gut microbiota and Metabolomics Malmö Offspring Study"
13:30-14:15 Ruth Loos, Icahn School of Medicine at Mount Sinai - New York City, US
"The genetics of obesity - From biology to precision medicine"
15:00-15:15 Coffee break
Session 3: Innovative use of big data
15.15-15.45 Naeimeh Atabaki-Pasdar, LUDC
"Optimising NAFLD diagnosis by developing a prediction tool as a proxy to MRI scans applying machine learning approaches: A DIRECT study"
15:45-16:30 Manolis Dermitzakis, University of Geneva, Switzerland
"From oligarchy to democrady in the genome: the 98% non-coding fraction takes charge"
Session 4: Precision medicine trials
16:45-17:15 Anders Rosengren, LUDC
"Genotype- and phenotypebased recall trials with type 2 diabetes patients"
17:15-17:45 Martin Ridderstråle, NovoNordisk, Denmark
"Combinations make perfect - academia and industry collaborations"
18:00 Paul Franks, LUDC
For registering, please send an e-mail to Pernilla [dot] Siming [at] med [dot] lu [dot] se at the latest November12th clearly stating:
- Participation with lunch
- Participation with dinner
- Any dietary requirements, if any
A no-show fee for SEK 500 if you register and do not show up